...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of substance abuse treatment >Preference for buprenorphinealoxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
【24h】

Preference for buprenorphinealoxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.

机译：在法国接受丁丙诺啡维持治疗的患者中首选丁丙诺啡/纳洛酮和丁丙诺啡：一项前瞻性，多中心研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Maintenance treatment with buprenorphine tablets (Subutex) has been associated with reductions in heroin use; however, concerns for intravenous misuse exist. A buprenorphinealoxone formulation (Suboxone) was designed to reduce this misuse risk while retaining buprenorphine's efficacy and safety. This prospective, open-label, multicenter trial compared preferences for buprenorphine and buprenorphinealoxone in 53 opioid-dependent patients stabilized on buprenorphine. Buprenorphine was first administered at the patient's current dose (Days 1-2), followed by a direct switch to buprenorphinealoxone (Days 3-5). Global satisfaction rates were high and similar between buprenorphine and buprenorphinealoxone; however, patients preferred the tablet taste, size, and sublingual dissolution time of buprenorphinealoxone. At the end of the study, 54% of patients preferred buprenorphinealoxone, 31% preferred buprenorphine, and 15% had no preference; most patients (71%) wished to continue treatment with buprenorphinealoxone. This study did not identify any impediments to a direct buprenorphine-to-buprenorphinealoxone switch and revealed some characteristics that may facilitate treatment with buprenorphinealoxone.
机译：丁丙诺啡片（Subutex）维持治疗已与减少海洛因的使用有关。然而，存在对静脉滥用的担忧。丁丙诺啡/纳洛酮制剂（Suboxone）旨在降低这种滥用风险，同时保留丁丙诺啡的功效和安全性。这项前瞻性，开放性，多中心试验比较了53名稳定于丁丙诺啡的阿片类药物依赖患者对丁丙诺啡和丁丙诺啡/纳洛酮的偏好。首先以患者当前剂量（1-2天）施用丁丙诺啡，然后直接转换为丁丙诺啡/纳洛酮（3-5天）。丁丙诺啡和丁丙诺啡/纳洛酮之间的总体满意度很高，相似;但是，患者更喜欢丁丙诺啡/纳洛酮的片剂味道，大小和舌下溶出时间。在研究结束时，54％的患者首选丁丙诺啡/纳洛酮，31％的患者首选丁丙诺啡，15％的患者无喜好;大多数患者（71％）希望继续使用丁丙诺啡/纳洛酮治疗。这项研究没有发现直接阻止丁丙诺啡向丁丙诺啡/纳洛酮转换的任何障碍，并且揭示了一些可能有助于丁丙诺啡/纳洛酮治疗的特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号